AR and cancer: We showed that common mouse models of cancer cachexia are refractory to anabolic androgen administration, but, in some cases, anti‐cachectic efficacy can be markedly improved by combined treatment with the HDACi AR‐42 (Figs 1, 2, 3, 4).